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It is well-recognized that research capability in veterinary species is restricted by a lack
of immunological reagents relative to the extensive toolboxes for small rodent biomedical
model species and humans. This creates a barrier to the strategic development of
disease control solutions for livestock, companion animals and wildlife that not only
affects animal health but can affect human health by increasing the risk of transmission
of zoonotic pathogens. There have been a number of projects aimed at reducing the
capability gaps in the veterinary immunological toolbox, the majority of these focusing
on livestock species. Various approaches have been taken to veterinary immunological
reagent development across the globe and technological advances in molecular biology
and protein biochemistry have accelerated toolbox development. While short-term
funding initiatives can address specific gaps in capability, they do not account for
long-term sustainability of reagents and databases that requires a different funding
model. We review the past, present and future of the veterinary immunological toolbox
with specific reference to recent developments discussed at the International Union of
Immunological Societies (IUIS) Veterinary Immunology Committee (VIC) Immune Toolkit
Workshop at the 12th International Veterinary Immunology Symposium (IVIS) in Seattle,
USA, 16–19 August 2019. The future availability of these reagents is critical to research
for improving animal health, responses to infectious pathogens and vaccine design as
well as for important analyses of zoonotic pathogens and the animal /human interface
for One Health initiatives.
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INTRODUCTION
The development of novel tools and technologies has been fundamental to the advancement of
basic and applied immunology across species. The rate of progress of immunological reagent
development for veterinary species has been much slower than that for humans and small rodent
biomedical model species, and has impacted research capability in those species (1). Historically,
however, innovations in surgical procedures in veterinary species have resulted in major step-
changes in our understanding of the ontogeny, compartmentalization and function of the immune
system. For example, bursectomy in chickens shed new light on mechanisms of B cell development
and immunoglobulin production (2), in utero thymectomy of lambs revealed the importance of
the thymus for lymphocyte development (3) and lymphatic cannulation of sheep revealed that
lymphocyte subsets differ between blood, afferent and efferent lymph (4). These ground-breaking
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experiments were feasible, in part, due to the size of the
species under investigation, particularly for the technique of
lymphatic cannulation due to the diameter of lymphatic vessels
in ruminants (5).
However, this momentum in veterinary immunological
studies was not maintained; the vast majority of technological
innovations and discoveries in immunology in the past 50 years
have been made in mice. The development of congenic mice,
differing at a single histocompatibility locus, was a fundamental
technological innovation in immunology that led to mice being
the primary species of choice for research. That pioneering
work of George Snell and the later capability of genetically
manipulating congenic mice has allowed immunologists to
ascribe functions to genes, molecules and cells with high
precision (6). The development of monoclonal antibody (mAb)
technology using congenic mice subsequently created almost
boundless opportunities for research in basic and translational
immunology (7).
The availability of mAbs that could phenotype cells and
detect cytokines by ELISA underpinned the discovery of
two distinct CD4+ve T-cell subsets in congenic mice (8).
The subsequent Th1/Th2 paradigm provided a fundamental
framework for investigating immune activation and regulation
that has expanded far beyond those original two subsets. Current
capability now extends to multi-parametric analyses such as
simultaneous fourteen-color flow cytometry that can identify 89
functionally-relevant CD4+ve T-cell subsets in human blood (9).
Mass cytometry (CyTOF) methods using panels of well over 40
conjugated antibodies are now allowing for even deeper analysis
of single cell expression, offering new insights into cellular
subsets and their differentiation (10, 11).
Such technologies cannot usually be applied directly to
different species since molecular differences in immunological
orthologs result in low cross-reactivity of reagents across species
(12) as affirmed by a recent comparison of reactivity of immune
protein reagents for other species with swine orthologs (13).
Thus, reagent development needs to be evaluated on a case-
by-case basis. Gaps in capability for veterinary species are
often prioritized based on the extensive mouse and human
immunological toolboxes. The expansion of the toolboxes has
revealed substantial differences in the ways that humans, mice
and veterinary species respond to disease and highlighted to
need for studying different species in their own right (14, 15).
There have been coordinated efforts to evaluate species cross-
reactivity of anti-human CD antigen mAbs through the animal
homologs section of the human leukocyte differentiation antigen
(HLDA) workshops: for horses (16), dogs (17), pigs (18), and
ruminants (19).
In an effort to generate greater international co-ordination
for immune reagent characterization activities, the International
Union of Immunological Societies (IUIS) Veterinary
Immunology Committee (VIC) supported a Toolkit Workshop
Abbreviations: BMGF, Bill & Melinda Gates Foundation; BBSRC, Biotechnology
and Biological Sciences Research Council; NIFA, National Institute of Food and
Agriculture; REEIS, Research, Education and Economics Information System; SG,
Scottish Government; USDA, United States Department of Agriculture.
at the 6th International Veterinary Immunology Symposium
(IVIS) in Upsala, Sweden in 2001. This set the scene for a series
of VIC Toolkit Workshops (20). It is almost 10 years since the
last published review of the veterinary immunology toolbox
from the IUIS VIC Toolkit Workshop at the 9th IVIS in Tokyo,
Japan (1). Here, we review progress over the past decade by
reporting on the IUIS VIC Toolkit Workshop at the 12th IVIS in
Seattle, USA in 2019 and take a forward look to the future of the
veterinary immunology toolbox.
THE PAST
The success of the HLDA workshops was based on good
co-ordination, high-quality work and collective effort by the
veterinary immunology community, as well as results from past
species-specific CDworkshops supported by IUIS VIC. Common
standards were applied to the distribution and evaluation of
anti-human CD reagents being assessed in different laboratories
and the collective generated data being reviewed centrally. The
outcome was an evidence-based assessment for the activity
of species cross-reactive mAbs, with affirmation that only a
limited number of mAb directed against human CD antigens
actually cross-react with other animal species (21). These
results instilled confidence in the performance of those reagents
and promoted their uptake by the research community and
industry, including companies that market and sell veterinary
immunological reagents.
Although the HLDA workshops were primarily focused on
evaluation of species cross-reactive antibodies, they played an
important role in informing of capability gaps and therefore
the prioritization of reagents for future development. A major
step-change in the way veterinary immunological reagent
development was supported came with the inception of a
UK Immunological Toolbox funded by the Biotechnology
and Biological Sciences Research Council (BBSRC) and the
Scottish Executive Environment and Rural Affairs Department
(SEERAD) in 2003. This was unique as it united several
laboratories within a single project to take a collective multi-
species approach to immunological reagent development. This
was followed by the Veterinary Immune Reagent Network
(VIRN) funded by United States Department of Agriculture
(USDA)/National Institute of Food and Agriculture (NIFA) in
the US in 2005. Both projects included the creation of databases
listing available veterinary immunological reagents, which will be
discussed later. They also expanded the emphasis frommAb anti-
CD antigens to expression of immune proteins (cytokines and
chemokines) and protein reactive mAbs. The US project included
direct collaboration with commercial partners to express these
immune proteins. The US and UK projects worked together
under a Memorandum of Understanding (MOU) to avoid
duplication of effort. This MOU was created in the absence of
a mechanism for joint international funding by the respective
national agencies. The structure, priorities and achievements
of these projects has been published previously (1). A key
output from these initiatives was an increased recognition of
the importance of coordinated, complementary approaches to
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reagent prioritization and development. Their success has also
been reflected by continued support for reagent development
initiatives by funders seeking to build on the significant benefits
from their original investments, with the assertion that long-term
sustainability is essential.
The funding for veterinary immunology reagent development
has changed over the past 10 years, moving from the multi-
species models of the UK Immunological Toolbox and US VIRN,
to single-species projects. With the exception of ruminants,
there is very little species cross-reactivity of veterinary reagents,
highlighting that the genes involved in immune responses
are amongst the most rapidly evolving in vertebrate genomes
(22, 23). However, this does not diminish their potential as
disease models. BBSRC and USDA/NIFA have supported reagent
development projects for ruminants, swine, horses, aquaculture
species and poultry in the past 10 years (Box 1). A barrier to
formal international collaboration was lifted in 2013 when
USDA/NIFA and BBSRC launched a pilot call to support animal
disease research of strategic importance to both the US and UK
which included the development of veterinary immunological
reagents for agriculturally-relevant animal species. The
swine toolkit was a landmark first transatlantic veterinary
immunology reagent project funded under this initiative
in 2015 (Box 1).
Although we have focused here on projects funded specifically
to develop reagents and supporting technologies, this is not
intended to ignore the veterinary immunological reagent
development that is conducted within disease-driven projects,
networks and within strategic programmes of government
research institutes across the globe. The challenge is in capturing
the outputs of these diverse activities. The websites of commercial
reagent suppliers and peer-reviewed publications are sources
of validated information on reagent activity. However, they do
not capture everything, a particular gap being the paucity of
“negative” data when reagents are found to be non-functional
or where repeated attempts fail to generate specific antibodies.
These are very valuable data as they can potentially prevent the
duplication of wasted effort. The solution lies in community
engagement for the sharing of knowledge on reagent availability
and performance. Workshops such as those hosted by IUIS VIC
Toolkit are a focal point for international information exchange,
but they do not have the facility to capture, store and disseminate
information at a detailed level. It has been recognized for
many years that a major unmet need in veterinary immunology
is the lack of centralized, non-commercial, searchable reagent
databases (20). The original UK Immunological Toolbox (2003–
2009) and the US VIRN (2005–2015) both created lists of
reagents but the databases were not sustainable beyond the
term of funding. This is not surprising as curation is time-
consuming, requiring expert knowledge of immunology and
information technology input to create web-based interfaces.
This also highlighted the problem of sustainability when there is
reliance on short-term funding for reagent development projects.
Finding solutions to these problems has been the focus of several
recent workshops as discussed below. One exception to this has
been the USDA Agricultural Research Service (ARS) supported
Porcine Translational Research database (PTRD, http://tinyurl.
com/hxxq3ur) (15).
THE PRESENT
The current landscape of the veterinary immunology toolbox
has been shaped by new funding approaches to facilitate reagent
development while also addressing the complex issues of database
construction, collection and validation of data, and sustainability
of the database and biobanks of the reagents listed therein.
This report summarizes the outcomes of several international
workshops where these various elements have been considered.
Before summarizing those outcomes, it is worth reviewing
the scope of the toolbox in terms of species coverage and
knowledge of immunological capability within those species. In
the broadest sense, the concept of a veterinary immunological
toolbox encompasses a broad range of livestock, companion
animal, biomedical model and wildlife species. There has been
progress in reagent development across all of those species
in the past 10 years which has been presented at various
meetings and workshops. We have identified a number of
published articles where reagent availability for different species
have been reviewed. For the purposes of the toolbox, livestock
species can largely be regarded as belonging to one of four
major groupings, namely swine (24, 25), ruminants (22, 26),
poultry (27–29), and aquaculture (30, 31). Companion animals
include horses (32, 33), cats (34), and dogs (35). As previously
discussed, mice are the most common small-animal biomedical
model for human (12). However, rabbits (36) and ferrets (37)
are also popular small-animal biomedical models for human
disease. There is interest in expanding the immunological
toolboxes for wildlife species, for example buffalo (38) and
badgers (39) due to their potential to act as reservoirs for
economically-important livestock diseases. There is also interest
in developing immunological reagents for marine mammals
such as dolphins (40). In addition, although camelid species are
not often regarded as a major target host species for disease
studies, they have come to the fore with heightened awareness
of MERS-CoV and the potential to reduce zoonotic transmission
by investigating vaccine-induced responses in camels (41).
Importantly, camels make a unique technological contribution
to the immunological toolbox via the production of nanobodies
(42, 43).
To date, the concept of the veterinary immunological toolbox
has largely (but not exclusively) focused on reagent development
for livestock species due to their strategic relevance for funders
with a stake in livestock health, food safety and global food
security. In the period between the last published review of the
IUIS VIC Toolkit Workshop at the 9th IVIS in Tokyo (1) and
the IUIS VIC Toolkit Workshop at the 12th IVIS in Seattle, there
have been several key meetings whose outcomes are directly
relevant to the current status and future directions of the toolbox
andmerit discussion here. The first was at the 10th IVIS inMilan,
Italy in 2013 when BBSRC and The Global Strategic Alliances for
the Coordination of Research on the major Infectious Diseases of
Animals and Zoonoses (STAR-IDAZ) supported a vaccinology
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BOX 1 | Veterinary immunological reagent and technology projects  rst funded in the period 2010–2020.
BMGF: Livestock Antibody Hub: Cattle, swine, poultry (2019–2024):
https://www.pirbright.ac.uk/news/2019/11/bill-melinda-gates-foundation-funds-development-pirbright%E2%80%99s-livestock-antibody-hub. To study cattle, pig
and poultry antibody responses at high resolution to expand the understanding of protective immunity in those species and that can also be used as models for a
range of human infectious diseases.
USDA/NIFA: Cattle (2019–2022):
https://portal.nifa.usda.gov/web/crisprojectpages/1016686-immune-reagents-for-ruminants-with-primary-focus-on-bovine-specific-reagents.html. To develop,
and make commercially available, mAb reagents needed to elucidate cattle immune mechanisms by focusing on CD antigens, cytokines, and chemokines and
relevant assays.
USDA/NIFA: Swine (2019–2022):
https://portal.nifa.usda.gov/web/crisprojectpages/1019192-development-of-new-swine-reagents-to-broaden-our-understanding-of-immune-correlates-of-
protection-and-microbial-pathogenesis.html. To generate priority reagents for swine immune proteins and pipeline them for marketing. Develop SLA class I tetramers
and new assays for important swine immune markers.
USDA/NIFA/BBSRC (US-UK Collaborative): Swine (2015–2019):
https://gtr.ukri.org/projects?ref=BB%2FM028232%2F1
https://portal.nifa.usda.gov/web/crisprojectpages/1005670-us-uk-collaborative-swine-immune-toolkit-development-of-new-immune-reagents-for-swine-health-
vaccine-and-disease-studies.html. To develop panels of mAb reactive with swine targets (cytokine, chemokines and their receptors) using conventional and
phage-display methods. Use resultant mAbs to develop new assays for swine immunity and make the reagents commercially available.
USDA/NIFA: Horse (2015–2019):
https://portal.nifa.usda.gov/web/crisprojectpages/1005524-equine-immune-reagents-development-of-monoclonal-antibodies-to-improve-the-analysis-of-
immunity-in-horses.html. To develop and characterize mAbs for the analysis of horse immunity and distribute these to the scientific community for immunological
research.
USDA/NIFA: Aquaculture (2016–2020):
https://portal.nifa.usda.gov/web/crisprojectpages/1009003-collaborative-immune-reagent-network-for-aquacultured-species.html. To develop and provide
immunological tools and assays to the aquaculture community to advance health for four fish species: rainbow trout, Atlantic salmon, channel catfish and Nile tilapia.
USDA/NIFA: Poultry (2017–2022):
https://reeis.usda.gov/web/crisprojectpages/1012306-development-of-poultry-immune-reagents.html. To identify chicken immune molecules, particularly
cytokines, chemokines and cell surface markers, express them as recombinant proteins, and characterize their function. Develop mAbs to the target molecules
and use these for multiplexed detection assays.
BBSRC/SG/BioRad: Cattle and Sheep (2012–2015):
https://bbsrc.ukri.org/research/grants-search/AwardDetails/?FundingReference=BB%2FI019863%2F1. To develop reagents and techniques to enable the
investigation of the activation and regulation of the immune systems of cattle and sheep with specific reference to cell-surface molecules, intracellular transcription
factors and cytokines that can define phenotypically-distinct macrophage, dendritic cell (DC) and T cell subsets.
USDA/NIFA: US Veterinary Immune Reagent Network (2010–2015):
https://portal.nifa.usda.gov/web/crisprojectpages/0221344-us-veterinary-immune-reagent-network.html. To clone, express, develop mAb reagents specific for
ruminants, swine, poultry, equine and aquaculture species, sharing methods across species. Work with commercial partner to market expressed proteins for use by
veterinary immunology community.
workshop. The lack of immunological tools and reagents was
recognized as a major barrier to progress. This can be seen in
the subsequent BBSRC Veterinary Vaccinology Strategy (https://
bbsrc.ukri.org/about/reviews/scientific-areas/1506-veterinary-
vaccinology-strategy/) and the creation of the BBSRC UK
Veterinary Vaccinology Network (VVN).
In 2017, BBSRC VVN hosted a workshop to discuss the
toolbox initiatives in the UK and US with specific relevance to
the aims and objectives of the newly-formed Global Challenges
Research Fund (GCRF) International Veterinary Vaccinology
Network (IVVN). A full report is available on the BBSRC VVN
website (http://www.vetvaccnet.ac.uk/publications/veterinary-
immunology-toolbox-meeting-uk-veterinary-vaccinology-
network). At this workshop, The Pirbright Institute and The
Roslin Institute at the University of Edinburgh announced plans
for a new UK Immunological Toolbox project. The combined
project would be underpinned by core Institute funding from
the BBSRC, with additional support from the BBSRC GCRF
Tools and Resources (https://www.immunologicaltoolbox.co.
uk/about/funders). This project is addressing major gaps in
capability and sustainability. The first of these is the creation
of a publicly accessible, searchable database of veterinary
immunological reagents to be accessed via a dedicated website.
A follow up meeting was held at the VVN Conference in Stirling
in early 2018 (https://www.vetvaccnet.ac.uk/news/2018/01/
uk-veterinary-vaccinology-network-conference-2018-report)
to discuss in more detail the focus of the website and new
reagent development. It was agreed by the community that a
key driver for the website would be the facility for researchers
to submit information on reagent performance and request
reagent production where gaps exist. It was discussed that the
primary focus of new reagent development should be around T
cell and B cell subsets to help dissect in more detail pathogen
and vaccine responses. As well as new reagent development
the toolbox aims to exploit new technologies to translate
current hybridoma stocks into gene blocks via sequencing and
create a recombinant antibody pipeline, express recombinant
proteins (including cytokines and chemokines), build multiplex
platforms and develop high-throughput screening systems for
new antibodies. These sequences act as the template from which
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the constant region can be switched between different species
while maintaining target specificity.
A toolkit workshop was held at the 6th European Veterinary
Immunology Workshop (EVIW) conference in Utrecht,
Netherlands in 2018. Although this conference was organized
under the auspices of the European Veterinary Immunology
Group (EVIG), as opposed to IUIS VIC, the IUIS VIC Toolkit
Committee took a leading role in the organization of the toolkit
workshop. Notably, the toolkit workshop was structured to
reflect four newly-formed major livestock groupings (swine,
ruminants, poultry, aquaculture) of IUIS VIC Toolkit which
were announced for the first time at this meeting. The leaders
of the species groups represented their respective areas at the
workshop. They are listed on the IUIS VIC webpage and can
be contacted by members of the community who are seeking
information or looking to engage in reagent development
for each of those areas (https://iuis.org/committees/vic/). The
workshop covered the major projects in Europe and the US on
reagent development, including a presentation on the plans for
the new UK Immunological Toolbox. In the panel discussion,
there was broad international support for the approaches
being taken within the new toolbox project and recognition
of the complementary work being supported by USDA/NIFA
in all of the target species (Box 1). This meeting cemented
the requirement for community engagement in the website
to provide and maximize information exchange about the
availability and performance of reagents and the focus on the
generation of novel antibodies and methods to distinguish T
and B cell subsets. This particular area will be advanced by
the development of a new Livestock Antibody Hub centered
at The Pirbright Institute which aims to improve both animal
and human health globally by translating research outcomes in
livestock diseases (Box 1). A core aim of this Antibody Hub is to
develop tools, techniques and reagents for livestock research that
bring the research capability to the same level as that for humans
and mice.
The IUIS VIC Toolkit workshop at the 12th IVIS in Seattle
was the forum for the international launch of the Pirbright/Roslin
UK Immunological Toolbox website and the associated database
(http://www.immunologicaltoolbox.co.uk). This database was
built around the original information collated during the 2003–
2009 BBSRC SEERAD-funded UK Immunological Toolbox and
is therefore skewed toward three of the four major livestock
groupings (swine, ruminants and poultry). However, aquaculture
species, companion animals and now major animal pathogens
are also included, and as the community engages the amount
of information will increase. The main aim of the website is
to collate reagent information and act as a centralized source
to increase information exchange but is not the only source
for any particular species. For example, the USDA Porcine
Translational Research Database (http://tinyurl.com/hxxq3ur)
is considered a very wide ranging and valuable community
resource and cannot be duplicated but information is shared
with the UK Immunological Toolbox via mutual awareness and
direct communication.
The UK Immunological Toolbox database contains data
on reagents that are held in research laboratories, and also
those available commercially, which immediately raises questions
on the quality and reproducibility of reagents from different
sources. The standardized production, evaluation and storage
of commercially-available reagents would be expected to reduce
batch-to-batch variation, whereas the same reagent produced
and stored in different research laboratories is likely to have
more variability due to the different conditions. When reagents
are listed on the UK Immunological Toolbox website there will
be information on their specificity and performance, preferably
supported by peer-review publication wherever possible.
There is also a facility for registered users to provide feedback
on performance to add to the available information. Such
information will be checked before posting against the user’s
identification. It was emphasized that such a database can be
as complete and useful as the community wants it to be. The
website and database will be curated centrally, but the community
has to take collective ownership by submitting reagents and
information on their performance. It is pleasing to see that
this is already happening. The toolbox website also serves as
a reference point for non-veterinary immunologists looking
to expand their choice of biomedical models and facilitate
comparative immunology research (44).
Finally, several new opportunities were identified during
the open discussion at the IUIS VIC Toolkit Workshop in
Seattle. These included the unique opportunity to salvage and
store “orphan” mAbs via the sequencing technology within the
UK Immunological Toolbox. The preservation of sequences
does not incur the high costs associated with maintaining
hybridoma cells in liquid nitrogen. In addition, the sharing
of sequences circumvents many of the logistical and financial
issues involved in the shipment of live cells, particularly across
international borders.
THE FUTURE
As we enter the third decade of the 21st century, the “OneHealth”
agenda has never been more important. The development
of solutions for controlling infectious diseases in livestock,
companion animals and wildlife not only has direct benefits for
the target species but can reduce disease transmission across
species, including zoonotic transmission, thereby reducing the
wider global disease burden (45). Close contact between different
animal species and between animals and humans is a risk for
zoonotic disease, which can be difficult to manage in low and
middle income countries (LMICs) (46). Given the importance
of livestock to LMICs, the veterinary immunological toolbox
provides economic and health benefits by underpinning animal
vaccine development.
The quality of toolbox reagents and associated information in
the UK Immunological Toolbox database are paramount.
Evidence-based validation and standardization of new
technologies is essential to generate confidence in performance
and encourage uptake by the community. There remain
major capability gaps in multi-analyte protein technologies for
veterinary species. The development of such technologies is
technically challenging, but entirely feasible with the appropriate
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resources and effort. The key to success is in working together.
The single-tube technology that simultaneously identifies 89
functionally-relevant CD4+ve T-cell subsets in human blood
was developed and validated through the collective efforts
of the multiple partners in the EuroFlow and PERISCOPE
consortia (9). Multiparametric technologies are extremely
powerful; one way of expanding the flexibility of the relatively
limited range of antibodies in veterinary species is the ability to
efficiently conjugate small amounts of antibodies with different
labels for defining immune correlates. The identification and
quantification of immunological correlates of protection are
aspirational goals for the development of safe and effective
vaccines (47, 48). However, with the exception of anti-virus
neutralizing antibodies, immunological correlates of protection
tend to be multifactorial rather than singular, particularly in the
case of cell-mediated protective immunity requiring not only cell
subset identification but appropriate cytokine co-expression. The
solution to identifying such correlates lies in the application of a
range of multi-plex technologies that all detect multiple analytes
at the genetic, protein, and cellular level, so called “systems
vaccinology” (49).
We are also moving into an era of high dependency
on computational infrastructure as the data generated by
such complex studies require specialized programmes for full
analysis. Hence, collective approaches are becoming increasingly
important if we are to maximize our potential to develop and
adopt complex technologies in the future. The importance of
genomic information and alternate expression systems such
as Pichia pastoris, insect and mammalian cells has meant
wider availability of species-specific immune proteins. The
veterinary immunology community has a long history of working
together for collective good, such as the HLDA workshops,
international CD workshops, toolkit committees, collaborative
funding initiatives and the immunological toolbox. In doing
so we need to maintain a global perspective and consider
technologies that create solutions for animal diseases across
borders. One example is the antibody sequencing technologies
of the new UK Immunological Toolbox. In addition to the
advantages described earlier, this technology offers particular
cost-effective and sustainability benefits for the transfer and
storage of reagents to LMICs where veterinary immunology
research is being conducted.
In parallel to sequencing, expressing and engineering mAbs,
companies and research groups all over the world are adapting
single B cell sequencing technologies to a range of host
species. These technologies often rely to some extent on
existing reagents to identify B cells (including antigen specific
B cells) but are generally very adaptable to any given species
and synergise well with existing mouse recombinant antibody
expression methods. These methods are providing a completely
new route to identifying antibodies against specific epitopes
on pathogens as well as other foreign immunizing antigens.
These antibodies can be used as reagents, including mapping
complex epitope landscapes to inform structural vaccinology
approaches to increase efficacy, and may also be used as
therapeutics. Antibodies are now a primary therapeutic goal of
many companies for a range of human diseases. Cats and dogs
are not only a profitable target market for immunotherapeutics,
they provide value data on in vivo mAb function (50).
Although the cost of such treatments is currently prohibitive
for food producing species, large animal models and species-
specific reagents can have a very important role in testing
manufacture, delivery and efficacy of mAbs as part of the One
Health approach.
The impact of veterinary immunology research will ultimately
be measured by the development, or contribution to the
development, of disease-control solutions including diagnostic
tests, vaccines and genetic-based strategies. The range of
vaccine-delivery platforms is rapidly expanding, including
improved adjuvants, vector-based delivery systems and
genetic vaccination with DNA and RNA. Although viral-
vectored vaccines are successfully deployed in humans and
companion animals (51), public safety concerns remain
regarding their use food animals (52). The immunological
toolbox can be applied to safety and efficacy studies in
livestock, thereby informing on the benefit-risk ratio that
would be impossible to do at the same scale in humans
or primates.
Animal genetics can provide insights into responses to
infection and vaccination which can be translated into livestock
breeding programmes (53, 54). Breeding programmes require
several generations to observe population effects and conclusive
proof for the effect of a specific genotype on immune status
requires functional evidence, hence reliance on the toolbox.
New gene-editing technologies such as CRISPR now allow very
targeted approaches to livestock production (55). This is the
future of livestock farming and the immunological toolbox
not only has a role to play in the identification of genes
to be targeted, but it will also be important for defining
subsequent immune function, including potential off-target
effects. Genome editing is also creating the opportunities to
engineer species to act as better models for human diseases
alongside or in addition to genetically defined and tailored
breeds, such as SCID pigs and MHC homozygous pigs (56,
57). For example, pigs are emerging as a very powerful
model to predict human influenza vaccine responses but to
achieve the maximum benefit of such models a complete
toolkit is required (58). Gene editing is already providing pig
organs for future human xenotransplantation, a biomedical
application that has helped drive reagent development in pigs
(59, 60).
CONCLUSION
The veterinary immunological toolbox is very broad in
its scope and has evolved from multiple efforts across
the globe. In the broadest sense, the toolbox incorporates
livestock, companion animals, wildlife and biomedical animal
species. Each is important in its own right, but all are
collectively important for the One Health agenda and for
controlling existing and emerging diseases that infect different
animal populations and have zoonotic potential. As human
populations expand, there is a need to protect food security
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without compromising food safety. Disease prevention and
control results in improvements in animal health and welfare,
which not only has economic and ethical benefits but
can also address concerns for climate change by making
food production more efficient. Basic immunology underpins
these approaches, from vaccine design to understanding the
effects of gene editing. The immunological toolbox website
and associated searchable database provides a new focal
point for information and knowledge exchange for the
veterinary immunology community. The key to future success
is global collective working facilitated by networks such as
national immunological societies, EVIW, IVVN, American
Association of Veterinary Immunologists (AAVI), and IUIS VIC
Toolkit Committee.
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